saw103

Scott A.. Waldman, MD, PhD

Contact Dr. Waldman

132 South 10th Street
Suite 1170
Philadelphia, PA 19107

(215) 955-6086
(215) fax

Most Recent Peer-reviewed Publications

  1. A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients
  2. Guanylyl cyclase C signaling axis and colon cancer prevention
  3. Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer
  4. Targeting guanylate cyclase C in colorectal cancer: Where are we now?
  5. GUCY2C ligand replacement to prevent colorectal cancer
  6. Big data transforms discoveryutilization therapeutics continuum
  7. Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis
  8. Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies
  9. Intestinal enteroids model guanylate cyclase C-dependent secretion induced by heat-stable enterotoxins
  10. Guanylyl cyclase C as a biomarker
  11. CD19-targeted nanodelivery of doxorubicin enhances therapeutic efficacy in B-cell acute lymphoblastic leukemia
  12. Companion diagnostics at the intersection of personalized medicine and healthcare delivery
  13. Clinical pharmacology & therapeutics: The next five years
  14. A novel CDX2 isoform regulates alternative splicing
  15. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C
  16. Managing the innovation supply chain to maximize personalized medicine
  17. Molecular insights provide the critical path to disease mitigation
  18. Selective antigen-specific CD4+ T-cell, but not CD8+ T- or B-cell, tolerance corrupts cancer immunotherapy
  19. Antiobesity pharmacotherapy: New drugs and emerging targets
  20. Policies to aid the adoption of personalized medicine